Reply to the Letter to the Editor regarding 'PFS, OS or toxicity: what is the most important factor in the treatment of EGFR-mutated lung cancer?' by T. Nishimura and H. Fujimoto

Felip, E.; Cho, B. C.; Nguyen, D.; Curtin, J. C.; Sethi, S.; Bauml, J. M.; Lee, S. H.

doi:10.1016/j.annonc.2024.10.011

YUHSpace

BROWSE

6 22

Cited 0 times in

Reply to the Letter to the Editor regarding 'PFS, OS or toxicity: what is the most important factor in the treatment of EGFR-mutated lung cancer?' by T. Nishimura and H. Fujimoto

Authors: Felip, E. ; Cho, B. C. ; Nguyen, D. ; Curtin, J. C. ; Sethi, S. ; Bauml, J. M. ; Lee, S. H.

Citation: ANNALS OF ONCOLOGY, Vol.36(2) : 221-222, 2025-02

Journal Title: ANNALS OF ONCOLOGY

ISSN: 0923-7534

Issue Date: 2025-02

Keywords: Amivantamab ; Dexamethasone ; Lazertinib ; Osimertinib ; Epidermal Growth Factor Receptor ; Amivantamab ; Dexamethasone ; Lazertinib ; Osimertinib ; Tetracycline Derivative ; Epidermal Growth Factor Receptor ; Cancer Chemotherapy ; Confidence Interval ; Drug Safety ; Follow Up ; Food And Drug Administration ; Hazard Ratio ; High Risk Population ; Human ; Infusion Related Reaction ; Letter ; Non Small Cell Lung Cancer ; Overall Survival ; Patient-reported Outcome ; Progression Free Survival ; Quality Of Life ; Rash ; Risk Benefit Analysis ; Toxicity ; Venous Thromboembolism ; Adult ; Drug Comparison ; Drug Therapy ; Female ; Letter ; Lung Cancer ; Major Clinical Study ; Male